Assistant Professor and Director of Urologic Oncology, The University of Illinois at Chicago

Urology

Doctor Michael R. Abern, MD is an expert in the field of Urology. He graduated from Rush Medical College. Michael Abern is also a published doctor. He has 34 paper published. The most recent paper is: Cystic Nephroma/Mixed Epithelial Stromal Tumor: A Benign Neoplasm With Potential for Recurrence. Dr. Michael R. Abern accepts all Medicare patients.

Publications

---

• Cystic Nephroma/Mixed Epithelial Stromal Tumor: A Benign Neoplasm With Potential for Recurrence.
• Androgen Deprivation Monotherapy for Localized Prostate Cancer: Can It Be Justified?
• Use of Nephron Sparing Surgery and Impact on Survival in Children with Wilms Tumor: A SEER Analysis.
• Survival of patients undergoing cytoreductive surgery for metastatic Renal cell carcinoma in the targeted-therapy era.
• The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate Cancer.
• Metformin does not affect risk of biochemical recurrence following radical Prostatectomy: results from the SEARCH database.
• The characteristics of Bladder cancer after radiotherapy for prostate cancer.
• Maintenance bacillus calmette-guérin: why is there continued debate?
• Short-term functional outcomes and complications associated with transperineal template Prostate mapping biopsy.
• Characteristics of patients diagnosed with both melanoma and renal cell Cancer.
• RADIATION EXPOSURE ASSOCIATED WITH DEDICATED Renal MASS COMPUTER TOMOGRAPHY PROTOCOL: IMPACT OF PATIENT CHARACTERISTICS.
• Perioperative intravesical chemotherapy in non-muscle-invasive Bladder cancer: a systematic review and meta-analysis.
• Interpreting a Study on Bladder Cancer Screening.
• The Effect Of Dietary Sodium And Fructose Intake On Urine And Serum Parameters Of Stone Formation In A Pediatric Mouse Model: A Pilot Study.
• Race is associated with discontinuation of active surveillance of low-risk prostate Cancer: results from the Duke Prostate Center.
• African-American men with low-grade prostate Cancer have higher tumor burdens: results from the Duke Prostate Center.
• Does a positive response to spermatic cord block predict response to microdenervation of the spermatic cord for Chronic scrotal content pain?
• Obesity is associated with worse oncological outcomes in patients treated with radical cystectomy.
• Evolution of the concept of focal therapy for prostate Cancer.
• Delayed radical prostatectomy for intermediate-risk prostate Cancer is associated with biochemical recurrence: possible implications for active surveillance from the S...
• Prostate Cancer Antigen 3 to Select Men for Prostate Biopsy: Stop, Go, or Proceed with Caution?
• Renal Mass Anatomic Characteristics and Perioperative Outcomes of Laparoscopic Partial Nephrectomy: A Critical Analysis.
• Long-term oncological outcomes of men undergoing radical Prostatectomy with preoperative Prostate-specific antigen <2.5 ng/ml and 2.5-4 ng/ml.
• Combination of Penile Traction, Intralesional Verapamil, and Oral Therapies for Peyronie's Disease.
• Predicting Erectile Dysfunction Following Surgical Correction of Peyronie's Disease without Inflatable Penile Prosthesis Placement: Vascular Assessment and Preoperativ...
• Marital status independently predicts testis Cancer survival-an analysis of the SEER database.
• Ureteral mullerianosis.
• Penile shortening after radical Prostatectomy and Peyronie's surgery.
• Ketoconazole and prednisone to prevent recurrent ischemic priapism.
• Persistent motile sperm after ligation band vasectomy.
• Hyperthermia as Adjunct to Intravesical Chemotherapy for Bladder Cancer.
• An update on TroVax for the treatment of progressive castration-resistant prostate Cancer.
• Peyronie''s disease: evaluation and review of nonsurgical therapy.

Schools

---

• Rush Med Coll Of Rush Univ

Procedures Preformed

---

• Cystourethroscopy and Transurethral Resection of Bladder Neck
• Kidney and Ureter Removal
• Kidney Stone Removal (Percutaneous Nephrostolithotomy, PCNL)
• Pelvic Exenteration (For: Gynecologic, Urinary, or Colorectal Malignancy)
• View All

Conditions Treated

---

• Bladder Cancer
• Bladder Infection
• Blood in Urine (Hematuria)
• Chronic Kidney Diseases
• View All

Doctors Specialties

---

• Urology

Accepted Insurances

---

• Aetna HMO
• Choice Plus POS II
• Open Access
• Cigna HMO
• Cigna PPO
• Great West Healthcare-Cigna PPO
• Platinum PPO
• First Health (Coventry Health Care) PPO
• HealthLink PPO
• Choice Care PPO
• MultiPlan PPO
• PHCS Network PPO
• Sagamore Plus

Education

---

• Duke University Hospital
• Rush University Medical Center
• Rush Medical College

Hospital

---

• University of Illinois Hospital & Health Sciences System

Drug Facts

---

NPI NUMBER		1033377403
NPPES Provider LastName		ABERN
NPPES Provider FirstName		MICHAEL
NPPES Provider ZIPCode		606124325
NPPES Provider State		IL
Specialty Description		Urology
Total Claim Count		22.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1033377403
Last Name Of The Provider	ABERN
First Name Of The Provider	MICHAEL
View All

Similar Doctors

---

	Dr. Michael Young, MD This Doctor is OpenDoctor Recommended.
	Dr. Ronald B. Neal, MD This Doctor is OpenDoctor Recommended.
	Dr. Christopher L. Coogan, MD This Doctor is OpenDoctor Recommended.
	Dr. William W. Lin, MD
	Dr. Michael C. Large, MD This Doctor is OpenDoctor Recommended.
	Dr. David M. Hatcher, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog